These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35311258)

  • 1. Hijacking Methyl Reader Proteins for Nuclear-Specific Protein Degradation.
    Nalawansha DA; Li K; Hines J; Crews CM
    J Am Chem Soc; 2022 Mar; 144(12):5594-5605. PubMed ID: 35311258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
    Gu S; Cui D; Chen X; Xiong X; Zhao Y
    Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolysis of methylated SOX2 protein is regulated by L3MBTL3 and CRL4
    Zhang C; Leng F; Saxena L; Hoang N; Yu J; Alejo S; Lee L; Qi D; Lu F; Sun H; Zhang H
    J Biol Chem; 2019 Jan; 294(2):476-489. PubMed ID: 30442713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules.
    Hickey CM; Digianantonio KM; Zimmermann K; Harbin A; Quinn C; Patel A; Gareiss P; Chapman A; Tiberi B; Dobrodziej J; Corradi J; Cacace AM; Langley DR; Békés M
    Nat Struct Mol Biol; 2024 Feb; 31(2):311-322. PubMed ID: 38177675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of Potent Ligands for the E3 Ligase DCAF15 and Evaluation of Their Use in Heterobifunctional Degraders.
    Lucas SCC; Ahmed A; Ashraf SN; Argyrou A; Bauer MR; De Donatis GM; Demanze S; Eisele F; Fusani L; Hock A; Kadamur G; Li S; Macmillan-Jones A; Michaelides IN; Phillips C; Rehnström M; Richter M; Rodrigo-Brenni MC; Shilliday F; Wang P; Storer RI
    J Med Chem; 2024 Apr; 67(7):5538-5566. PubMed ID: 38513086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A synthetic KLHL20 ligand to validate CUL3
    Farrell BM; Gerth F; Yang CR; Yeh JT
    Genes Dev; 2022 Sep; 36(17-18):1031-1042. PubMed ID: 36328355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PROTACs: A novel strategy for cancer drug discovery and development.
    Han X; Sun Y
    MedComm (2020); 2023 Jun; 4(3):e290. PubMed ID: 37261210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution.
    Xiao Y; Yuan Y; Liu Y; Lin Z; Zheng G; Zhou D; Lv D
    J Med Chem; 2024 Jul; 67(14):11580-11596. PubMed ID: 38981094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation.
    Sobierajski T; Małolepsza J; Pichlak M; Gendaszewska-Darmach E; Błażewska KM
    Drug Discov Today; 2024 Jul; 29(7):104032. PubMed ID: 38789027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of AlphaFold models in evaluating ligandable cysteines across E3 ligases.
    Koldenhof P; Bemelmans MP; Ghosh B; Damm-Ganamet KL; van Vlijmen HWT; Pande V
    Proteins; 2024 Jul; 92(7):819-829. PubMed ID: 38337153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROTACs: An Emerging Therapeutic Modality in Precision Medicine.
    Nalawansha DA; Crews CM
    Cell Chem Biol; 2020 Aug; 27(8):998-1014. PubMed ID: 32795419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.
    Zografou-Barredo NA; Hallatt AJ; Goujon-Ricci J; Cano C
    Bioorg Med Chem; 2023 Jun; 88-89():117334. PubMed ID: 37224698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target protein localization and its impact on PROTAC-mediated degradation.
    Simpson LM; Glennie L; Brewer A; Zhao JF; Crooks J; Shpiro N; Sapkota GP
    Cell Chem Biol; 2022 Oct; 29(10):1482-1504.e7. PubMed ID: 36075213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges.
    Wang C; Zhang Y; Zhang T; Shi L; Geng Z; Xing D
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1667-1693. PubMed ID: 35702041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications.
    Ward CC; Kleinman JI; Brittain SM; Lee PS; Chung CYS; Kim K; Petri Y; Thomas JR; Tallarico JA; McKenna JM; Schirle M; Nomura DK
    ACS Chem Biol; 2019 Nov; 14(11):2430-2440. PubMed ID: 31059647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PHOTACs Enable Optical Control of Protein Degradation.
    Reynders M; Trauner D
    Methods Mol Biol; 2021; 2365():315-329. PubMed ID: 34432252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROTACs in gastrointestinal cancers.
    Chen Y; Yang Q; Xu J; Tang L; Zhang Y; Du F; Zhao Y; Wu X; Li M; Shen J; Ding R; Cao H; Li W; Li X; Chen M; Wu Z; Cho CH; Du Y; Wen Q; Xiao Z
    Mol Ther Oncolytics; 2022 Dec; 27():204-223. PubMed ID: 36420306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation.
    Kagiou C; Cisneros JA; Farnung J; Liwocha J; Offensperger F; Dong K; Yang K; Tin G; Horstmann CS; Hinterndorfer M; Paulo JA; Scholes NS; Sanchez Avila J; Fellner M; Andersch F; Hannich JT; Zuber J; Kubicek S; Gygi SP; Schulman BA; Winter GE
    Nat Commun; 2024 Jun; 15(1):5409. PubMed ID: 38926334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ELIOT: A platform to navigate the E3 pocketome and aid the design of new PROTACs.
    Palomba T; Baroni M; Cross S; Cruciani G; Siragusa L
    Chem Biol Drug Des; 2023 Jan; 101(1):69-86. PubMed ID: 35857806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.